← Back to all trials
Not Yet Recruiting
NCT07753993
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Conditions: Chronic Kidney Disease
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 7000
Sponsor: AstraZeneca
Location: Research Site Sheffield Alabama
Summary
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Eligibility Criteria
Inclusion Criteria:
* Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges.
* On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.
Exclusion Criteria:
* BMI \
Source: ClinicalTrials.gov (NCT07753993). StuddyBuddy aggregates publicly available trial information.
